Probe comes after three members of the drug advisory board resigned in protest.
On Friday, Food and Drug Administration Acting Commissioner Dr. Janet Woodcock called for an independent investigation of the Alzheimer’s drug Aduhelm. On June 7, the drug was approved to treat Alzheimer’s. An earlier vote from the FDA advisory committee said that there was not enough evidence to support the drug’s effectiveness, and three members of the board resigned after the drug was approved.
In a letter posted to social media, the acting commissioner said, “There continue to be concerns raised, however, regarding contacts between representatives from Biogen and FDA during the review process, including some that may have occurred outside of the form correspondence process. To the extent these concerns could undermine the public’s confidence in FDA’s decision, I believe that it is critical that the events at issue be reviewed by an independent body such as the Office of the Inspector General.”
As the Lord Leads, Pray with Us…
- That the FDA would have discernment in evaluating and authorizing medications.
- For Acting Commissioner Woodcock to seek God’s wisdom as she leads the FDA.
- That God would guide the Inspector General to the best course of action with this case.
Sources: CNN, NY Times, Washington Post
